

AD \_\_\_\_\_

Award Number: DAMD17-02-1-0439

TITLE: The Functions of BRCA2 in Homologous Recombinational  
Repair

PRINCIPAL INVESTIGATOR: David J. Chen, Ph.D.

CONTRACTING ORGANIZATION: University of California at Berkeley  
Berkeley, California 94720

REPORT DATE: July 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

Best Available Copy

20050516 059

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

|  |   |  |  |                                  |
|--|---|--|--|----------------------------------|
| <b>1. AGENCY USE ONLY</b><br>(Leave blank)   |   | <b>2. REPORT DATE</b><br>July 2004                             | <b>3. REPORT TYPE AND DATES COVERED</b><br>Annual (1 Jul 03 - 30 Jun 04) |                                  |
| <b>4. TITLE AND SUBTITLE</b><br>The Functions of BRCA2 in Homologous Recombinational Repair  |   |  | <b>5. FUNDING NUMBERS</b><br>DAMD17-02-1-0439                            |                                  |
| <b>6. AUTHOR(S)</b><br>David J. Chen, Ph.D.  |   |  |  |                                  |
| <b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b><br>University of California at Berkeley<br>Berkeley, California 94720<br><br>E-Mail: DJChen@lbl.gov  |   |  | <b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>                          |                                  |
| <b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b><br>U.S. Army Medical Research and Materiel Command<br>Fort Detrick, Maryland 21702-5012   |   |  | <b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>                  |                                  |
| <b>11. SUPPLEMENTARY NOTES</b>   |   |  |  |                                  |
| <b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b><br>Approved for Public Release; Distribution Unlimited   |   |  |  | <b>12b. DISTRIBUTION CODE</b>    |
| <b>13. ABSTRACT (Maximum 200 Words)</b><br><br>Using an HR assay system, we found that individual expression of several small BRCA2 regions in human HT1080 cells causes a reduced frequency in homologous recombination. Our data provide the direct cellular evidence that the BRCA2-Rad51 interaction is crucial for HR repair and multiple regions of BRCA2 protein are involved in regulating HR repair. Using the baculovirus co-expression and Ni-NTA pull-down strategies, we demonstrated that BRCA2 forms a multiprotein complex with Rad51, Rad51B and Rad51C DNA repair proteins involving a strong interaction between BRCA2 and Rad51, and between Rad51B and Rad51C. A weak interaction between Rad51 and Rad51C was observed as well. We also found that the BRC repeats of BRCA2 do not directly interact with Rad51B or Rad51C. In addition, we have successfully expressed three BRC fragments using baculovirus expression system. These protein expressions were confirmed by Western analysis. The purification of these proteins was found to be difficult because these proteins were extremely unstable and tended to be degraded during the purification process. We have tested several conditions to stabilize the proteins, including use of different salts, different concentration of salts, different expression temperature, and co-expression of the proteins with Rad51. We have established three biochemical assays for Rad51 activities, including DNA binding, ATPase and DNA strand exchange. The investigation regarding whether the BRC1-4, BRC5-8 or BRC1-8 proteins affects the Rad51 activities is underway. |   |  |  |                                  |
| <b>14. SUBJECT TERMS</b><br>BRCA2 Protein, Breast Cancer, DNA Repair   |   |  |  | <b>15. NUMBER OF PAGES</b><br>44 |
|  |   |  |  | <b>16. PRICE CODE</b>            |
| <b>17. SECURITY CLASSIFICATION OF REPORT</b><br>Unclassified   | <b>18. SECURITY CLASSIFICATION OF THIS PAGE</b><br>Unclassified | <b>19. SECURITY CLASSIFICATION OF ABSTRACT</b><br>Unclassified | <b>20. LIMITATION OF ABSTRACT</b><br>Unlimited                           |                                  |

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102


**Table of Contents**

|  |            |
|--|------------|
| <b>Cover.....</b>                        | <b>1</b>   |
| <b>SF 298.....</b>                       | <b>2</b>   |
| <b>Table of Contents.....</b>            | <b>3</b>   |
| <b>Introduction.....</b>                 | <b>4</b>   |
| <b>Body.....</b>                         | <b>4-8</b> |
| <b>Key Research Accomplishments.....</b> | <b>8-9</b> |
| <b>Reportable Outcomes.....</b>          | <b>9</b>   |
| <b>Conclusions.....</b>                  | <b>9</b>   |
| <b>References.....</b>                   | <b>10</b>  |
| <b>Appendices.....</b>                   | <b>10</b>  |

## INTRODUCTION

The BRCA2 gene is associated with hereditary tendency to breast cancer [1, 2]. Exactly how defects in BRCA2 causes predisposition to breast cancer is not yet understood. Recent evidence indicates that the BRCA2 protein has a critical function in DNA repair through homologous recombination (HR) [3-6]. It is very likely that defective HR repair causes the accumulation of unrepaired DNA in genome and results in cancers. We propose to investigate how BRCA2 functions in DNA HR repair using both cellular and biochemical approaches.

The BRCA2 gene encodes a large protein of 3418 amino acids with a molecular weight of 384-kDa [7, 8]. The BRCA2 protein physically interacts with Rad51, the key protein in DNA HR repair, via two Rad51-binding domains, eight BRC repeats [3] and an extreme C-terminal region (amino acids 3196-3232) [9-11]. These eight conserved BRC repeats (designated as BRC1 to BRC8) [12], located in the central portion of the protein and cover nearly a third of the protein. These two Rad51-binding domains of BRCA2 have been shown to be essential for normal sensitivity to DNA-damaging agents, indicating they are functionally significant. Therefore, we focus our efforts on investigation of the effects of these Rad51-interacting regions of BRCA2 in HR repair. The domain constructs used in our study are diagrammed in Fig. 1. Our specific aims and research progress are summarized in the following:




## BODY

**Specific aim 1.** To test the hypothesis that disruption of the BRCA2-Rad51 interaction affects homologous recombination (HR) in human HT1080 cells. We propose that the human BRCA2 participates directly to homologous recombination through the interaction with Rad51 and regulates this process in some critical way, such that disruption of the BRCA2-Rad51 interaction results in a reduction in the capacity of repairing chromosome breaks by HR. We established a cellular approach to assay HR frequency *in vivo*. To measure HR, an artificial reporter locus was installed into a chromosome of human HT1080 cells and clones of cells that integrated the reporter were isolated. A defined DNA double-strand break can be introduced at the integrated reporter locus, by transient expression of a highly site-specific endonuclease I-SceI of *S. cerevisiae* [13-15]. This reporter locus can detect repair of a specifically I-SceI

induced chromosomal double-strand break by HR. The HT1080 cells harboring the reporter were therefore used for the HR assay.


#### **Progress:**

Using this HR assay system, we investigated the effects of three BRCA2 regions, including a BRC1 motif and two C-terminal fragments (BRCA2-A and BRCA2-D). Fragment BRCA2-A consists of amino acids 3206-33310 and fragment BRCA2-D consists of amino acids 3179-3418. We found that transient expression of the BRC1 motif of BRCA2 during double-strand break induction in HT1080 cells caused a great suppression (~22-fold) as compared with the control (vector alone) in the frequency of HR (Fig. 2.). The result suggests that the BRCA2-Rad51 interaction through BRC1 is important for regulating HR repair, such that disruption of the normal protein-protein interaction between BRCA2 and Rad51 by overexpression of the small BRCA2 domain causes impaired HR. In addition, expression of fragment BRCA2-A or BRCA2-D in HT1080 cells resulted in a smaller but significant reduction in the HR frequency (Fig. 3.), indicating that the C-terminal region of BRCA2 also plays a role in the function of BRCA2 in HRR. Our results provide direct cellular evidence that the BRCA2-Rad51 interaction is crucial for HR repair and that multiple regions of BRCA2 protein are involved in regulating HR repair.



**Fig. 2. Expression of BRC1 motif of BRCA2 greatly inhibits repair of a chromosome break by homologous recombination**

To understand whether expression of larger BRC fragments causes a dominant negative effect or facilitates the HR repair *in vivo*, we further examined the effects of larger BRC domains of BRCA2 on HRR. We have PCR amplified the BRC1-4, BRC5-8, and BRC1-8 fragments of BRCA2 using the full-length BRCA2 cDNA as a template and individually constructed each fragment into a pIRESHyg2 mammalian expression vector. Each BRC constructs were individually transfected into HT1080 cells harboring the HRR reporter and the HR assays with expression of each fragment are currently underway.




**Fig. 3. Expression of C-terminal fragments of BRCA2 causes smaller but significant reductions in HR frequency**

**Specific aim 2.** To test the hypothesis that the BRCA2 protein functions to mediate the biochemical activities of Rad51. It is not clear how the Rad51-BRCA2 interaction regulates DNA homologous recombinational repair. We hypothesize that BRCA2 directly mediates the biochemical activities of Rad51 [16-18] and subsequently affects homologous recombination. To investigate the effects of BRCA2 protein on


the Rad51 activities, we proposed to purify the BRCA2 protein and examine its effects on Rad51 using three biochemical assays, including DNA binding, ATPase and DNA strand exchange. Because the very large size of BRCA2 might hamper attempts to obtain the full-length protein, we decided to purify the functional domain of BRCA2, the BRC repeats. We proposed to express and purify three BRC fragments, including BRC1-4, BRC5-8 and BRC1-8 (as indicated in Fig. 1). The purification of the human Rad51 protein is required for the assays as well.

#### **Progress on protein purification:**

We have expressed the human Rad51 protein in insect cells Sf9 using the baculovirus system. The Rad51 protein was subsequently purified to homogeneity using spermidine precipitation and sequential column chromatography with hydroxyapatite, Q-Sepharose, heparin affinity and MonoQ column (Fig. 4.). We have been able to obtain about 10 mg of the purified Rad51 protein during our study and this amount of the protein is sufficient for the biochemical assays. To obtain the BRCA2 protein, we constructed the BRC1-4, BRC5-8 and BRC1-8 fragments of BRCA2 (as diagrammed in Fig. 1.) into a 6xHis-tagged baculoviral vector. Employing the baculovirus strategies, we successfully expressed the three BRC fragments of BRCA2 in Sf9 cells. The BRC1-4, BRC5-8, and BRC1-8 domains encode the proteins of 80-kDa, 65-kDa, and 138-kDa, respectively. The identity of these proteins was confirmed by Western Blotting using either  $\alpha$ -BRC4 or  $\alpha$ -BRC5 antibody as well as  $\alpha$ -His



**Fig. 4. Purified human Rad51, Rad51B and Rad51C proteins**



**Fig. 5. Baculovirus expression of BRC1-4 and BRC1-8 fragments.** Cells were harvested on days 2, 3, 4, 5 post-infection of baculoviruses


#### **Progress on activity assays:**

We established three *in vitro* assays for Rad51 activity, including DNA binding, ATPase and DNA strand exchange. Using these biochemical assays, we examined the activity for Rad51 and Rad51 paralogs, Rad51B and Rad51C. We also examined the effects of small BRCA2 domains on the activity of Rad51.


**1) DNA binding assay.** We established a gel shift assay to determine the DNA binding activity using [ $^{32}$ P]-labeled oligonucleotides, including single-stranded DNA (ssDNA) 63mer, double-stranded DNA (dsDNA) 63/63mer, and 3'-tailed dsDNA 63/32mer. Using this assay, we have examined the DNA binding activity of Rad51 and two Rad51 paralogs, Rad51B and Rad51C [19]. We demonstrated that Rad51B and Rad51C bind both ssDNA and dsDNA, and show preference for tailed dsDNA. We also compared the DNA binding

capabilities of Rad51B and Rad51C with Rad51 using the same three DNA substrates: 63mer, 63/63mer and 63/32mer. We found that Rad51C possesses a higher affinity for all of three DNAs than does Rad51. The relative affinity of these three proteins for DNA was found to be: Rad51C > Rad51 > Rad51B. Using these DNA substrates, the effect of the BRC1-4, BRC5-8 and BRC1-8 fragments on the DNA binding activity of Rad51 is currently investigated.

**2) ATPase assay.** We established an *in vitro* ATPase assay using [ $\gamma$ - $^{32}$ P]ATP as the substrates and have determined the ATPase activity of the Rad51, Rad51B and Rad51C proteins [19]. We also examined whether the BRC1 domain of BRCA2 has effects on the ATPase activity of Rad51. As shown in Fig. 6., various ratios of BRC1 and Rad51 were tested in the assay and an inhibitory effect on the ATPase activity of Rad51 was observed. We found that the ATPase activity of Rad51 was inhibited at approximately 4.0 fold with the molar ratio of BRC1 and Rad51 is equal to 2 and that the inhibitory effect was slightly increased as the BRC1/Rad51 ratio increases. The inhibitory effect of the BRC1 domain on the ATPase activity of Rad51 indicates that the BRC1 domain of BRCA2 is important for regulating the ATP binding and/or hydrolysis of Rad51.



**3) DNA strand exchange assay.** The key biochemical activity of Rad51 in the recombinational DNA repair process is to promote strand pairing and exchange between two homologous DNA strands. It is important to investigate whether BRCA2 acts to mediate the DNA strand exchange activity of Rad51 and leads to effects on homologous recombination. We established a DNA strand transfer assay using ssDNA 63mers and [ $^{32}$ P]-labeled dsDNA 32/32mers as the substrates. The DNA strand transfer activity of Rad51 was determined as a control. The strand transfer products (3'-tailed 63/32mer) were observed and the amount of product formation is dependent on the concentration of Rad51. We also demonstrated that Rad51C displays apparent DNA strand transfer in an ATP-independent manner [19], while Rad51B shows no such activity (Fig. 7.). The effects of BRC1-4, BRC5-8 and BRC1-8 on the DNA strand transfer activity of Rad51 are currently under investigation.




**Specific aim 3. To test the hypothesis that the BRCA2 protein forms a stable complex with Rad51 and two Rad51 paralogs, Rad51B and Rad51C.** Using a baculovirus co-expression system and Ni-NTA pull-down strategies, we demonstrated that Rad51 and two Rad51 paralogs (Rad51B and Rad51C) interact simultaneously and form a multiprotein complex. We propose to demonstrate that BRCA2 is an essential

component in the Rad51-dependent recombinational complex, interacting with Rad51, Rad51B, and Rad51C to form a stable complex using a gel filtration column. In addition, we also investigated whether BRCA2 directly interacts with Rad51B or Rad51C.

#### **Progress:**

Using baculovirus system, we co-expressed the 6xHis-tagged BRC1-4 (or BRC1-8) domain of BRCA2 with untagged Rad51, Rad51B and Rad51C in Sf9 cells. The Ni-NTA magnetic beads were used to pull-down 6xHis-tagged BRC1-4 (or BRC1-8) protein and the associated proteins. We examined the pull-downed fractions using Western blotting analysis with  $\alpha$ -BRC,  $\alpha$ -Rad51,  $\alpha$ -Rad51B and  $\alpha$ -Rad51C antibodies. We found that a large amount of Rad51 was pull-downed by BRC fragments as well as a little amount of Rad51C and Rad51B. The result indicates that BRCA2 interacts simultaneously with Rad51, Rad51B and Rad51C, and forms a complex with these proteins *in vitro* (Fig. 8.). It also shows that the interaction between the BRC repeats of BRCA2 and Rad51 is strong and BRC1-4/Rad51 (or BRC1-8/Rad51) interacts weakly with Rad51C/Rad51B heterodimer through the interaction between Rad51 and Rad51C.

In addition, to examine whether the BRC repeats of BRCA2 interacts directly with Rad51 paralog Rad51B (or Rad51C), we co-expressed the 6xHis-tagged BRC1-4 (or BRC1-8) fragment and untagged Rad51B (or Rad51C) proteins in Sf9 insect cells. We tested BRC1-4/Rad51B, BRC1-8/Rad51B, BRC1-4/Rad51C and BRC1-8/Rad51C. The protein expressions were confirmed using Western blotting analysis with  $\alpha$ -BRC4,  $\alpha$ -BRC5,  $\alpha$ -Rad51B and  $\alpha$ -Rad51C antibodies. The Ni-NTA magnetic beads were used to bind the 6xHis-tagged BRC domains and whether the untagged Rad51B (or Rad51C) can be pull-downed by the BRC domains was examined. We found that no detectable Rad51B or Rad51C was observed in the pull-downed fraction with either BRC1-4 or BRC1-8 fragment. The results suggest that there is no direct interaction between the BRC repeats of BRCA2 and Rad51B, or BRCA2 and Rad51C.



Together, our data demonstrated that: (1) BRCA2 forms a multiprotein complex with Rad51, Rad51B and Rad51C through a strong interaction between BRCA2 and Rad51 and a weak interaction between Rad51 and Rad51C. (2) There is no direct interaction between the BRC repeats of BRCA2 and Rad51B (or Rad51C).

#### **KEY RESEARCH ACCOMPLISHMENTS**

1. The effect of overexpression of a BRC1 motif and two C-terminal fragments (amino acids 3206-3310 and 3179-3418) of the BRCA2 protein on DNA repair via homologous recombinational (HR) was directly determined by an *in vivo* HR assay. Our results provide direct cellular evidence that BRCA2-Rad51 interaction is crucial for HR repair and that the multiple regions of BRCA2 protein are involved in regulating HR repair.
2. The human Rad51 protein was expressed in insect cells and purified to homogeneity using spermidine precipitation and sequential column chromatography. We have obtained 10 mg of purified Rad51 protein and this amount of the protein is sufficient for the biochemical assays.



3. The BRC1-4 and BRC1-8 fragments of BRCA2 were expressed. We discovered that these BRC proteins were extremely unstable and tended to be degraded during the purification process. We have been working on several approaches to solve the problem.
4. We found that the BRC1 domain of BRCA2 suppresses the ATPase activity of human Rad51. The result indicates that the BRC1 domain of BRCA2 functions to modulate the ATP binding/hydrolysis of Rad51.
5. We found that BRCA2 forms a multiprotein complex with Rad51, Rad51B and Rad51C through a strong interaction between BRCA2 and Rad51 and a weak interaction between Rad51 and Rad51C.
6. We found that there is no direct interaction between the BRC repeats of BRCA2 and Rad51B (or Rad51C).

#### REPORTABLE OUTCOMES

1. An abstract "Lio, Y-C, Schild, D, Brenneman, MA, Redpath, JL, and Chen, DJ. siRNA depletion of Rad51C suppresses homologous recombination frequency and causes hypersensitivity to mitomycin C in human cells." was presented in American Association for Cancer Research Special Conference at Dana Point, California in February 2004.
2. A manuscript related to this project entitled "Human Rad51C deficiency destabilizes XRCC3, impairs recombination and radiosensitizes S/G<sub>2</sub>-phase cells." was submitted for publication.

#### CONCLUSIONS

Using an HR assay system, we found that individual expression of several small BRCA2 regions in human HT1080 cells causes a reduced frequency in homologous recombination. These results indicate that disruption of the normal BRCA2-Rad51 interaction by introducing the small BRCA2 fragments impairs homologous recombination. Our data provide the direct cellular evidence that the BRCA2-Rad51 interaction is crucial for HR repair and multiple regions of BRCA2 protein are involved in regulating HR repair.

Using the baculovirus co-expression and Ni-NTA pull-down strategies, we demonstrated that BRCA2 forms a multiprotein complex with Rad51, Rad51B and Rad51C DNA repair proteins involving a strong interaction between BRCA2 and Rad51, and between Rad51B and Rad51C. A weak interaction between Rad51 and Rad51C was observed as well. We also found that the BRC repeats of BRCA2 do not directly interact with Rad51B or Rad51C.

In addition, we aim to purify the Rad51-binding domain (BRC repeats) of BRCA2 and investigate its effects on Rad51 activities. We have successfully expressed three BRC fragments using baculovirus expression system, including BRC1-4, BRC5-8 and BRC1-8. These protein expressions were confirmed by Western analysis using specific antibodies. The purification of these proteins was found to be difficult because these proteins were extremely unstable and tended to be degraded during the purification process. We have tested several conditions to stabilize the proteins, including use of different salts, different concentration of salts, different expression temperature, and co-expression of the proteins with Rad51. We have established three biochemical assays for Rad51 activities, including DNA binding, ATPase and DNA strand exchange. We found that the BRC1 domain of BRCA2 inhibits the ATPase activity of Rad51, indicating a role for the BRC1 domain in modulating the ATP binding and/or hydrolysis activity of Rad51. The investigation regarding whether the BRC1-4, BRC5-8 or BRC1-8 proteins affects the Rad51 activities are underway.

## REFERENCES

1. Stratton, MR and Wooster, R. (1996) Hereditary predisposition to breast cancer. *Curr Opin Genet Dev* 6: 93-7
2. Arver, B. *et al.* (2000) Hereditary breast cancer; a review. *Semin Cancer Biol* 10: 271-288
3. Wong, AKC *et al.* (1997) RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene *brca2*. *J Biol Chem* 272: 31941-31944
4. Patel KJ *et al.* (1998) Involvement of *Brca2* in DNA repair. *Mol Cell* 1: 347-357
5. Abbott, DW *et al.* (1998) Double-strand break repair deficiency and radiation sensitivity in *BRCA2* mutant cancer cells. *J Natl Cancer Inst* 90: 978-985
6. Chen, PL *et al.* (1998) The BRC repeats in *BRCA2* are critical for RAD51 binding and resistance to methyl methanesulfonate treatment. *Proc Natl Acad Sci USA* 95: 5287-5292
7. Bertwistle, D *et al.* (1997) Nuclear location and cell cycle regulation of the *BRCA2* protein. *Cancer Res* 57: 5485-5488
8. Tavtigian, SV *et al.* (1996) The complete *BRCA2* gene and mutations in chromosome 13q-linked kindreds. *Nat Genet* 12: 333-337
9. Mizuta, R *et al.* (1997) *RAB22* and *RAB163*/mouse *BRCA2*: proteins that specifically interact with the *RAD51* protein. *Proc Natl Acad Sci USA* 94: 6927-6932
10. Sharan, SK *et al.* (1997) Embryonic lethality and radiation hypersensitivity mediated by *Rad51* in mice lacking *Brca2*. *Nature* 386: 804-810
11. Morimatsu, M *et al.* (1998) Cells deleted for *Brca2* COOH terminus exhibit hypersensitivity to gamma-radiation and premature senescence. *Cancer Res* 58: 3441-3447
12. Bork, P *et al.* (1996) Internal repeats in the *BRCA2* protein sequence. *Nat Genet* 13: 22-23
13. Rouet, P *et al.* (1994) Introduction of double-strand breaks into the genome of mouse cells by expression of a rare-cutting endonuclease. *Mol Cell Biol* 14: 8096-8106
14. Chouliska, A *et al.* (1995) Induction of homologous recombination in mammalian chromosomes by using the *I-SceI* system of *Saccharomyces cerevisiae*. *Mol Cell Biol* 15: 1968-1973
15. Brenneman MA *et al.* (2000) *XRCC3* is required for efficient repair of chromosome breaks by homologous recombination. *Mutat Res* 459: 89-97.
16. Benson, FE *et al.* (1994) Purification and characterization of the human *Rad51* protein, an analogue of *E coli RecA*. *Embo J* 13: 5764-5771
17. Baumann, P *et al.* (1996) Human *Rad51* protein promotes ATP-dependent homologous pairing and strand transfer reactions in vitro. *Cell* 87: 757-766
18. Baumann, P *et al.* (1997) The human *Rad51* protein: polarity of strand transfer and stimulation by *hRP-A*. *Embo J* 16: 5198-5206
19. Lio, Y-C, Mazin AV, Kowalczykowski, SC and Chen DJ (2003) Complex formation by the human *Rad51B* and *Rad51C* DNA repair proteins and their activities in vitro. *J Biol Chem* 278: 2469-2478

## APPENDICES

1. Lio, Y-C, Schild, D, Brenneman, MA, Redpath, JL, and Chen, DJ (2004) Human *Rad51C* deficiency destabilizes *XRCC3*, impairs recombination and radiosensitizes S/G<sub>2</sub>-phase cells. *J. Biol. Chem.* submitted.

**Human Rad51C deficiency destabilizes XRCC3, impairs recombination and radiosensitizes S/G<sub>2</sub>-phase cells\***

Yi-Ching Lio<sup>1,2</sup>, David Schild<sup>1</sup>, Mark A. Brennenman<sup>3</sup>, J. Leslie Redpath<sup>2</sup> and David J. Chen<sup>1</sup>

<sup>1</sup>Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA;

<sup>2</sup>Department of Radiation Oncology, University of California, Irvine, Irvine, CA 92697, USA;

<sup>3</sup>Department of Genetics, Rutgers University, Piscataway, NJ 08854, USA.

To whom correspondence should be addressed:

Yi-Ching Lio  
MS74-157, Life Sciences Division  
Lawrence Berkeley National Laboratory  
One Cyclotron Road  
Berkeley, CA 94720  
Phone: (510) 486-5861  
Fax: (510) 486-6816  
e-mail: YLio@lbl.gov

**Running title:** Human Rad51C functions in homologous recombination

**Keywords:** homologous recombination/Rad51C/radiosensitivity/RNA interference/XRCC3

\* This work was supported by the U.S. Department of Energy under contract DE-AC03-76SF00098, U.S. Department of Defense grant, DAMD17-02-1-0439 and a California Breast Cancer Research Program grant, 7KB-0019 to Y.-C. L. and D.J.C.; National Institutes of Health grants GM030990 and CA092584 to D.S.; U.S. Department of Energy grant DE-FG-03-02ER63309 to J.L.R.; and U.S. Army Breast Cancer Research Program postdoctoral fellowship award DAMD17-00-1-0367 to M.A.B.

## SUMMARY

The highly conserved Rad51 protein plays an essential role in repairing DNA damage through homologous recombination. In vertebrates, five Rad51 paralogs (Rad51B, Rad51C, Rad51D, XRCC2, XRCC3) are expressed in mitotically growing cells, and are thought to play mediating roles in homologous recombination, though their precise functions remain unclear. Among the five paralogs, Rad51C was found to be a central component present in two complexes, Rad51C-XRCC3 and Rad51B-Rad51C-Rad51D-XRCC2. We have previously shown that the human Rad51C protein exhibits three biochemical activities, including DNA binding, ATPase and DNA duplex separation. Here we report the use of RNA interference to deplete expression of Rad51C protein in human HT1080 and HeLa cells. In HT1080 cells, depletion of Rad51C by small interfering RNA caused a significant reduction of frequency in homologous recombination. The level of XRCC3 protein was also sharply reduced in Rad51C-depleted HeLa cells, suggesting that XRCC3 is dependent for its stability upon heterodimerization with Rad51C. In addition, Rad51C-depleted HeLa cells showed hypersensitivity to the DNA cross-linking agent mitomycin C, and moderately increased sensitivity to ionizing radiation. Importantly, the radiosensitivity of Rad51C-deficient HeLa cells was evident in S and G<sub>2</sub>/M phases of the cell cycle but not in G<sub>1</sub> phase. Together, these results provide direct cellular evidence for the function of human Rad51C in homologous recombinational repair.

## INTRODUCTION

In mammalian cells, DNA double-strand breaks (DSBs)<sup>1</sup> are repaired primarily by two distinct mechanisms (reviewed in references 1, 2): non-homologous end joining (NHEJ), a non-templated, potentially error-prone process in which nucleotide alternations are tolerated at the site of rejoining, and homologous recombination (HR), a largely error-free process in which a sister chromatid or homologous chromosome is used as a template for repair. Homologous recombinational repair (HRR) provides high fidelity in repairing DNA damage, and is therefore essential and critical for the maintenance of genome stability and tumor avoidance (reviewed in references 3, 4). The Rad51 protein plays a key role in HR, functioning to mediate homologous DNA pairing and strand exchange (5, 6). Five vertebrate Rad51 paralogs are expressed in mitotically growing cells: Rad51B (7-9), Rad51C (10), Rad51D (9, 11, 12), XRCC2 (13-15), and XRCC3 (13, 16, 17). These proteins share 20-30% sequence identity with Rad51 and with each other. Only vertebrates appear to contain all five of these Rad51 paralogs. In human cells, Rad51C participates in various paralog complexes, including Rad51B-Rad51C, Rad51C-XRCC3, and Rad51B-Rad51C-Rad51D-XRCC2 (18-22). In terms of protein-protein interactions, Rad51C apparently has a central role, interacting directly with Rad51B, Rad51D, XRCC3, and also weakly with Rad51 (23, 24). However, the functional significance of these complexes is not yet clear.

Mutant studies provide a direct means for identifying the function of genes. A knockout mutation of Rad51C was previously generated in DT40 chicken B-lymphocyte cells (25). The mutant cells showed elevated spontaneous chromosomal aberrations, high sensitivity to killing by the cross-linking agent mitomycin C (MMC), mild sensitivity to  $\gamma$ -rays, and defective Rad51 nuclear focus formation after exposure to  $\gamma$ -rays. Similar phenotypes were also found in DT40

knockouts generated for the other four paralogs (25, 26), suggesting that each of the paralogs functions in HRR, and that fully efficient repair may require all five. In addition, two hamster cell lines, *irs3* and CL-V4B, have been identified as Rad51C mutants and both were found to show reduced sister chromatid exchange and genomic instability (27, 28). However, how Rad51C functions in human cells has not yet been understood and no Rad51C-mutant human cell line has been available.

RNA interference (RNAi) has rapidly emerged as a powerful technique for investigating gene function (29-32), and a valuable complement to mutant studies. RNAi is a sequence-specific post-transcriptional gene silencing mechanism that uses double-stranded RNA as a signal to trigger the degradation of homologous mRNA (33, 34). Chemically synthesized duplexes of 21-25 nucleotide small interfering RNA (siRNA) can induce specific gene silencing in a wide range of mammalian cell lines without causing apoptosis (35-38).

To determine the functions of Rad51C in human cells, we have previously used *in vitro* assays to demonstrate that the purified human Rad51C protein exhibits DNA binding, ATPase, and double-stranded DNA separation activities (24). These findings underscore the potential significance of the human Rad51C in the DNA strand exchange events of HR. Additionally, it was recently reported that Rad51C is required for Holliday junction processing in human extracts (39), implying a role for Rad51C in the resolution of HR intermediates. Here we report the depletion of Rad51C expression in two human cell lines, a fibrosarcoma line HT1080 and a cervical carcinoma line HeLa, using 21-nucleotide siRNA duplexes, and we directly examine the effect of Rad51C inhibition on HR, using an *in vivo* HR assay. The effect of Rad51C depletion on the endogenous level of other Rad51 paralogs in HeLa cells was also examined. In addition, the sensitivity of Rad51C-depleted HeLa cells to mitomycin C (MMC) and ionizing radiation

(IR) was characterized, and the dependence of radiosensitivity in Rad51C-deficient HeLa cells upon cell cycle phase was investigated, using synchronized G<sub>1</sub> and S+G<sub>2</sub>/M populations.

## EXPERIMENTAL PROCEDURES

*Rad51C siRNA design* — The siRNA duplexes were designed according to published procedures (36, 38) by selecting sense and anti-sense oligoribonucleotides homologous to the mRNA sequence. siRNA #1 is approximately 80 bases from the initiating AUG codon and siRNA #2 is about 120 bases before the carboxyl-terminal encoding sequence. Both siRNA #1 and #2 are complementary 21-mers with a two-base overhang, and start at an AA dinucleotide in the mRNA. Selected sequences were subjected to BLAST analysis to rule out homology to other human mRNA sequences. The siRNAs were synthesized by Dharmacon Research and provided as purified and annealed duplexes (38). The siRNA sequences of Rad51C used in the study are: siRNA #1: CUCCUAGAGGUGAAACCCUtt; siRNA #2: GUCACCCAGCCAGAAGGAAtt

*Cell Culture and siRNA transfection* — The human HT1080-1885 and HeLa cell lines were cultured as monolayers in minimal essential medium ( $\alpha$ -MEM) supplemented with 10% fetal bovine serum (Hyclone) and penicillin-streptomycin (Gibco BRL). The cells were maintained in a humidified 4.3% CO<sub>2</sub> incubator at 37°C. Twenty-four hours prior to transfection, cells were seeded in a 6-well plate at 400,000 cells per well. For each well, 15  $\mu$ l of siRNA stock oligonucleotide (20  $\mu$ M) was diluted into 0.26 ml of Opti-MEM (Gibco BRL). In a separate tube, 6  $\mu$ l of Oligofectamine transfection reagent (Invitrogen) was diluted into 17  $\mu$ l of Opti-

MEM and incubated at room temperature for 10 min. The Oligofectamine dilution was added into the diluted siRNA duplex and incubated at room temperature for 20 min. For control, cells were mock-transfected with Oligofectamine alone. Cells were washed twice with Opti-MEM, and 1.2 ml of Opti-MEM was subsequently added to each well. The Oligofectamine-siRNA complex was added drop-wise to the cells and incubated at 37°C. After 6 h, 0.75 ml of  $\alpha$ -MEM media supplemented with 30% fetal bovine serum was added to each well without removing the transfection mixture, and the cells were returned to incubation at 37°C. Cells were harvested for assay of Rad51C expression by Western blotting analysis at 48, 72, and 96 h post-transfection.

*Antibodies* — Rad51B and Rad51C antibodies were generated as described previously (24). Polyclonal antiserum against human Rad51D was raised in rabbits using a synthetic peptide (CGTWGTSEQSATLQGDQT, Zymed Lab) as immunogen. The Rad51D antibody was affinity-purified from the antiserum. Rad51 antibody was kindly provided by Dr. Akira Shinohara. Both XRCC2 and XRCC3 antibodies were kind gifts of Dr. Nan Liu. QM antibody was purchased from Santa Cruz Biotechnology, Inc.

*Homologous recombination assays* — Human HT1080-1885 cells were treated with siRNA transfection (or mock-transfection) as described above. Two days after transfection, both sets of cells were trypsinized and individually seeded in a 6-well plate at 400,000 cells per well. The next day, each well was transfected with 1  $\mu$ g of I-SceI expression vector pCMV(3xNLS)I-SceI and 4  $\mu$ l of Superfect transfection reagent (Qiagen), or transfected with Superfect alone in serum-free  $\alpha$ -MEM media at a final volume of 1 ml. After 5-h incubation at 37°C, the transfection mixture was removed, and 3 ml of complete  $\alpha$ -MEM was added into each well, and the cells



were returned to incubation at 37°C. Twenty-four hours after I-SceI transfection, cells were replated in duplicate for puromycin selection, at 120,000 cells per 100-mm culture dish. Parallel platings for measurement of plating efficiency were made in duplicate at 250 cells per 100-mm dish. On day 2 after transfection with I-SceI, selection cultures were refed with fresh media containing 1 µg/ml puromycin. Cells were refed again with puromycin on days 6 and 10. Thirteen days after plating, cells were fixed and stained. The cultures for plating efficiency assay were incubated at 37°C for eleven days without refeeding, then fixed and stained. Colonies with fifty cells or more were counted.

*Mitomycin C and  $\gamma$ -ray survival using asynchronous cells* — Two days after siRNA transfection, HeLa cells were trypsinized and seeded at 1,000 cells per 100-mm dish for each mitomycin C (MMC) dose to be tested. After a four-hour incubation at 37°C, cells were treated with graded concentrations (0-2 µM) of MMC for 1 h at 37°C. The MMC-containing medium was then removed and replaced with 10 ml of complete  $\alpha$ -MEM medium, and the cells were returned to incubation at 37°C for colony formation. After eleven days, cell colonies were fixed and stained for counting. For  $\gamma$ -irradiation treatment, cells were seeded at 200-6,000 cells per T25 flask for each radiation dose to be tested. Cells were irradiated with a  $^{137}\text{Cs}$   $\gamma$ -ray source at a dose rate of 1.50 Gy/min for various doses (0-10 Gy) at room temperature, then returned to incubation at 37°C for colony formation. After eleven days, cell colonies were fixed and stained for counting.

*Cell synchronization and flow cytometry* — HeLa cells were synchronized in late G<sub>1</sub> phase using the plant amino acid mimosine (40-42). Cells were treated with 200 µM mimosine

(Calbiochem) for 16 h. At the end of this period, the mimosine-containing medium was removed and the cultures were washed three times with fresh media. Cells were thus released from mimosine blockade and allowed to proceed through the cell cycle. The distribution of cells in the phases of the cell cycle was assessed by flow cytometric analysis. At intervals after release from mimosine, cells were prepared by standard methods using propidium iodide staining of DNA (43). Measurements of cell cycle distribution were performed using a FACScan flow cytometer (Becton-Dickinson) and data were analyzed using MODFIT software.

*γ-ray survival using synchronous cells* — HeLa cells were transfected with Rad51C siRNA (or mock-transfection) as described above. Two days after transfection, both sets of cells were individually synchronized using mimosine treatment. The mock-transfected cultures were irradiated with various doses of γ-rays (0-10 Gy) at time point 0 or 7.5 h after release from mimosine, and the siRNA-transfected cultures were irradiated at 0 or 10 h after release from mimosine. After irradiation, cells were immediately trypsinized and replated in triplicate at 200-10,000 cells per T25 flask for each radiation dose to be tested. A parallel set of cells was returned to incubation at 37°C and replated in triplicate for colony formation after an 18-h delay. After eleven days of incubation, cell colonies were fixed and stained for counting.

## RESULTS

*Inhibition of Rad51C reduces the level of XRCC3 protein and other Rad51 paralogs* — To determine optimal conditions for depleting the expression of the Rad51C protein, nine different transfection condition sets with siRNA #1 were examined in HeLa cells, varied by siRNA

concentration, seeded cell density, and presence or absence of serum. Western analysis was used to monitor the expression level of Rad51C after siRNA treatment. Among the nine condition sets tested, one condition set achieved about 90% inhibition of the endogenous level of the Rad51C protein in HeLa cells (data not shown). This condition was therefore used as our standard protocol for Rad51C depletion, as described in EXPERIMENTAL PROCEDURES, for both HeLa and HT1080 human cells.

It has been shown that Rad51C directly interacts with Rad51, Rad51B, Rad51D and XRCC3, and together they form multiprotein complexes (18-24). We examined the endogenous levels of Rad51 and the other four Rad51 paralogs in Rad51C siRNA-transfected HeLa cells on days 2, 3 and 4 post-transfection. As shown in Fig. 1A, the cellular level of Rad51C decreased on day 2 after siRNA treatment and remained very low through days 3 and 4. Both siRNA #1 and #2 caused a similar level and time course of inhibition, indicating that these two siRNA duplexes are almost equally effective for suppressing Rad51C expression. Concomitantly with Rad51C inhibition, XRCC3 protein level was also greatly reduced on days 2, 3 and 4 post-siRNA transfection. The result indicates that depletion of Rad51C destabilizes XRCC3, presumably due to decreased formation of the stabilizing Rad51C-XRCC3 heterodimer. When the expression levels of Rad51 and Rad51B was examined, it was found that Rad51 level was low on day 2, but recovered by day 3. Similarly, Rad51B level was reduced on day 3, but recovered by day 4. These observations suggest that the level of Rad51C present may dynamically affect the expression or stability of Rad51 and Rad51B as well as XRCC3. In contrast, the inhibition of Rad51C had minimal effect on the level of Rad51D and XRCC2, indicating that Rad51C is not required for stabilization of these two proteins. The entire experiment was carried out three times and similar results were obtained. The Western data were quantified by densitometry and

statistical analysis for three independent experiments was shown in Fig. 1B. Mixed siRNA #1 and #2 was also used for transfection, and a similar pattern of Rad51 paralog levels was observed (data not shown). The marked dependence of XRCC3 upon Rad51C for its stability is important, and means that other results described below may reflect depletion of Rad51C, or XRCC3, or both (*i.e.*, the Rad51C-XRCC3 heterodimer).

*Inhibition of Rad51C results in a reduced frequency of homologous recombination* — To measure HR, an artificial reporter locus (as diagrammed in Fig. 2A) was installed into a chromosome of human HT1080 cells by electroporation with a vector, pPGKpacIR-BSD, that carries the complete reporter locus. Clones of cells that integrated the reporter were isolated by selecting for a blasticidin resistance gene included on the vector, and the presence of a single integrated copy was confirmed by Southern blotting (data not shown). The reporter locus comprises two defective Pac (puromycin acetyltransferase) genes configured as an inverted repeat. The left copy of the Pac gene has complete regulatory sequences (the murine phosphoglycerate kinase promoter/enhancer and the SV40 polyadenylation region), but is defective because of a mutation that deletes 80 base pairs of coding sequence, and creates a cleavage site for the highly site-specific endonuclease I-SceI of *S. cerevisiae* (44–47). The right copy of the Pac gene has an intact reading frame and a polyadenylation region, but is defective because it lacks a promoter. A defined DNA double-strand break can be introduced at the integrated reporter locus, by transient expression of I-SceI. Cleavage by I-SceI creates a double-strand break within the left Pac gene of the reporter locus. HR initiated from the break can convert the left Pac gene back to a wild-type sequence, by using the right copy as a template. Frequency of HR is scored by counting puromycin-resistant colonies of cells. HT1080-1885 is a clonal isolate of HT1080 cells stably carrying the reporter, and produces puromycin-resistant

colonies at a frequency of  $\sim 5 \times 10^{-3}$  per viable cell upon transient transfection for I-SceI expression (data not shown).

Rad51C siRNA #1 and #2 were individually transfected into HT1080-1885 cells. Two days after siRNA transfection, the cells were transiently transfected for expression of I-SceI endonuclease. Twenty-four hours after I-SceI transfection, a portion of the cells was subjected to Western analysis for Rad51C expression and a portion was replated for HR assay. As shown in Fig. 2B, both siRNA #1 and #2 duplexes inhibited the expression of the Rad51C protein by about 70% in HT1080-1885 cells. Using the *in vivo* HR assay, we found that the frequency of HR was reduced about 2-fold in the Rad51C siRNA-treated cells by both siRNA duplexes, as compared with the mock-transfected controls (t-test; siRNA #1,  $P = 0.0088$ ; siRNA #2,  $P = 0.0049$ ) (Fig. 2C). Our data provide direct *in vivo* evidence that human Rad51C functions in HRR.

*Suppression of Rad51C causes increased sensitivity to mitomycin C and ionizing radiation*  
— Cells defective in HR show hypersensitivity to a number of DNA-damaging agents, but are particularly sensitive to agents that form interstrand crosslinks, such as mitomycin C (MMC). We examined the sensitivity of Rad51C siRNA-transfected HeLa cells using acute exposure to MMC. We found that the siRNA-treated cells were  $\sim 2$ -fold more sensitive to MMC as compared with mock-transfected control based on the estimated  $D_{10}$  values (*i.e.*, the dose that reduces survival to 10%) (Fig. 3A). The MMC sensitivity profile of siRNA #1-treated cells was very similar to that of siRNA #2-treated cells, in accord with the similar depletion levels of Rad51C produced by the two siRNA duplexes. The plating efficiencies of mock-transfected control and siRNA-transfected HeLa cells were about 70% and 50%, respectively (data not shown). Mock-transfected and untransfected HeLa cells had similar sensitivity to MMC (data

not shown), indicating that our transfection protocol does not alter the sensitivity of HeLa cells to MMC. The HeLa control cells were much more sensitive to MMC ( $D_{10}$  about 1.3  $\mu$ M) as compared with V79 hamster cells ( $D_{10}$  about 30  $\mu$ M) (13) under acute conditions.

To determine the effects of IR on Rad51C-depleted HeLa cells, we first examined asynchronous cultures. Mock- and siRNA-treated cells were irradiated with various doses (0, 4, 6, 8, 10 Gy) of  $\gamma$ -rays. Suppression of Rad51C with siRNA transfection in HeLa cells resulted in mildly increased sensitivity to  $\gamma$ -rays as compared with mock-transfected controls (Fig. 3B). Both siRNA #1- and siRNA #2-transfection caused a similar effect on HeLa cells to  $\gamma$ -ray sensitivity. Treatment with the transfection reagent (Oligofectamine) alone had no effect on  $\gamma$ -ray sensitivity in HeLa cells (data not shown).

*Rad51C siRNA treatment alters cell cycle progression, and increases radiosensitivity in S and G<sub>2</sub>/M phases, but not in G<sub>1</sub> phase* — Because homologous recombination is an important pathway for repairing DNA DSBs in mammalian cells, particularly in S and G<sub>2</sub> phases of the cell cycle (48-50), we investigated whether the IR sensitivity of Rad51C-deficient HeLa cells is cell-cycle dependent. The plant amino acid mimosine inhibits cell cycle traverse in late G<sub>1</sub> phase, and can effectively synchronize mammalian cells (40-42). HeLa cells were treated with mimosine for 16 hours and then released to progress through the cell cycle. This technique produced an excellent synchrony for HeLa cells as described previously (42). Using this approach, Rad51C siRNA #1-treated HeLa cells and mock-transfected controls were synchronized. Flow cytometry was used to determine the percentage of the cell population in each cycle phase, and the results were plotted (Fig. 4). The distribution of mock-transfected HeLa cells through the cell cycle (Fig. 4A) was very similar to that previously observed for

untreated cells (42), *i.e.*, the majority of cells were in G<sub>1</sub> phase immediately following release from mimosine, whereas S phase and G<sub>2</sub>/M phases represent the majority at 6.5 and 11.5 h, respectively, after release from mimosine. This indicates that transfection with Oligofectamine did not affect the cell cycle progression. However, Rad51C siRNA treatment resulted in delayed progression through the cycle after release from mimosine, with S- and G<sub>2</sub>/M-phase cells reaching maxima at 10 and 12.5 hours, respectively (Fig. 4B). Based on these results, we chose two specific time points to irradiate the synchronous cell cultures with  $\gamma$ -rays. In the mock-transfected control populations enriched for G<sub>1</sub>- and S+G<sub>2</sub>/M-phase are predominant at 0 and 7.5 h after release from mimosine, respectively, and the cells were accordingly irradiated at 0 or 7.5 h after release. For the Rad51C siRNA-treated cells, however, the populations enriched for G<sub>1</sub> and S+G<sub>2</sub>/M phases are predominant at 0 and 10 h after release from mimosine, respectively, and these cells were therefore irradiated at those times.

HeLa cells were synchronized using mimosine treatment and irradiated with various doses of  $\gamma$ -rays at the time points determined above. After irradiation, cells were replated at low density either immediately or after an 18-h delay, and assayed for colony-forming ability. For the population enriched for S+G<sub>2</sub>/M phase, the Rad51C siRNA #1 and #2-treated cells were found to be ~1.2-fold more sensitive to IR as compared with the mock-transfected control (Fig. 5A) using the immediate plating protocol, as assessed by D<sub>10</sub> values. This modestly increased radiosensitivity is similar to that observed for asynchronous cells (Fig. 3B). Interestingly, the siRNA-treated G<sub>1</sub>-enriched cells did not show any additional sensitivity to  $\gamma$ -rays as compared with the mock-transfected G<sub>1</sub> cells (Fig. 5A). These important findings indicate that human Rad51C functions in repair of IR-induced DNA damage specifically in S and G<sub>2</sub>/M phases, but not in G<sub>1</sub> phase, and supports a role of Rad51C in HRR. The mock-transfected control cells

displayed greater radiosensitivity in G<sub>1</sub> than in the S and G<sub>2</sub>/M phases (Fig. 5A). This observation is in agreement with earlier studies in HeLa cells by Terasima and Tolmach (51, 52), who found that radioresistance is greatest in the latter stage of S phase, and that G<sub>1</sub>-phase cells are comparatively more sensitive to IR. Although the radioresistance of siRNA-treated S+G<sub>2</sub>/M-enriched cells was less than that of control S+G<sub>2</sub>/M-enriched cells, it did not fall to the level of G<sub>1</sub> cells (Fig. 5A). This suggests that HRR in S and G<sub>2</sub> phases is impaired but not abolished in the siRNA-treated cells, possibly reflecting the incomplete inhibition of Rad51C.

In addition to the immediate plating after  $\gamma$ -irradiation, a parallel set of cells was returned to 37°C incubation and then replated after an 18-h delay. It has been observed that the fraction of cells surviving a given dose of IR increases if a time interval is allowed between irradiation and replating because, during this interval, potentially lethal damage (PLD) is repaired (53-55). As shown in Fig. 5B, the surviving fraction of Rad51C siRNA- and mock-transfected cells was increased, in both populations enriched for G<sub>1</sub> and S+G<sub>2</sub>/M phases, with delayed plating compared to that with immediate plating (Fig. 5A). In the G<sub>1</sub> phase, no difference in IR sensitivity between Rad51C siRNA-treated cells and the control was observed (Fig. 5B). This result is consistent with the results obtained with immediate plating (Fig. 5A), suggesting that Rad51C inhibition does not affect the repair of PLD in G<sub>1</sub> phase. Importantly, we found that Rad51C siRNA-treated cells displayed a greater IR sensitivity than the control in the population enriched for S+G<sub>2</sub>/M phase (Fig. 5B), and that this difference was somewhat larger (1.4-fold) than that observed with immediate plating (Fig. 5A). This result suggests that Rad51C depletion inhibits the repair of PLD in S+G<sub>2</sub> phase and thus results in a higher radiosensitivity. Both the immediate and delayed plating experiments were carried out twice and consistent results were



obtained. Our findings suggest a role for human Rad51C in repairing DSBs induced by  $\gamma$ -irradiation that is specific to the S+G<sub>2</sub> phase of the cell cycle.

## DISCUSSION

*Rad51C dynamically influences the protein levels of other Rad51 family members* — The five mitotic Rad51 paralogs have been shown to form two distinct complexes in human cells, *i.e.*, a heterodimer of Rad51C-XRCC3, and a larger complex comprising Rad51B, Rad51C, Rad51D, and XRCC2 (18, 20-22). The transient existence of Rad51B-Rad51C and Rad51D-XRCC3 heterodimers has also been suggested (21, 22, 56). It seems probable that the various paralog complexes form dynamically during the process of HR (21). In these complexes, Rad51C interacts directly with XRCC3, Rad51B and Rad51D. Rad51C was also shown to weakly interact with Rad51 *in vitro* (23, 24). The previous protein-protein interaction data have suggested a central role for Rad51C among the five paralogs. Our findings of dynamic correlations between the expression level of Rad51C and those of XRCC3, Rad51 and Rad51B in Rad51C-deficient HeLa cells support this concept. Particularly, our results indicate that Rad51C directly stabilizes XRCC3, most probably through participation in the Rad51C-XRCC3 heterodimer. In cells treated with siRNA against Rad51C, XRCC3 protein levels were reduced nearly as much as Rad51C, and remained low over three days. This dependence upon heterodimerization appears to be mutual: in complementary experiments, it was previously shown that overexpression of XRCC3 produces an elevated level of Rad51C as well (20). Rad51C appears also to affect the expression or stability of Rad51 and Rad51B, though to a lesser extent and more transiently. It is interesting that the expression of Rad51D and XRCC2

seemed not to correlate with Rad51C expression, perhaps reflecting weaker or indirect associations between these proteins. The co-depletion of Rad51C and XRCC3 we observed in cells treated with siRNA against Rad51C has an important implication for the other results obtained in this study. The phenotypic changes we report in regard to frequency of HRR, MMC sensitivity, and IR sensitivity might, in principle, be attributable to deficiency of either Rad51C or XRCC3. However, we favor the possibility that these changes reflect a reduced level of functions carried out by the Rad51C-XRCC3 heterodimer.

*Our results provide direct in vivo evidence for the function of human Rad51C in HRR —* Mutant studies with chicken and hamster cells have implied a role for Rad51C in HRR (25, 27, 28). Very recently, it was reported that the hamster cell line irs3 has reduced homology-directed repair of a DNA DSB by gene conversion (57). However, no evidence of the biological functions of Rad51C has been available from human cells. Our results demonstrate a reduced frequency of repair of a specific chromosomal DSB by recombination after Rad51C siRNA treatment, thereby providing direct evidence that Rad51C functions in HRR in human cells. Although the observed reduction in HR frequency in Rad51C-depleted HT1080 cells is modest, the difference was reproducible and statistically significant. The incomplete inhibition of HR is likely due to partial depletion of Rad51C in siRNA-transfected HT1080 cells; approximately a 70% reduction as assessed by Western blot. It is possible that constitutive expression of siRNA would produce a more effective inhibition of Rad51C, and thus further decrease the frequency of HR. Further work remains to confirm this speculation.

Hypersensitivity to interstrand crosslinking agents such as MMC is a consistent feature of HRR-deficient mutants in vertebrate cell lines. It was previously reported that Rad51C-knockout

chicken DT40 cells are ~3-fold more sensitive than wild-type to MMC after acute exposure (25), and that the Rad51C-mutant hamster *irs3* and CL-V4B cell lines are ~20-fold and ~32-fold more sensitive to chronic treatment with MMC, respectively (27, 28). Our results show that the Rad51C-deficient HeLa cells display ~2-fold greater sensitivity to MMC using acute treatment, demonstrating that these cells have a similar phenotype for MMC sensitivity to that of the chicken and hamster mutants. An *XRCC3* gene knockout in the human colon cancer cell line HCT116 has been recently reported, and the *XRCC3*-deficient cells showed ~2-fold excess sensitivity to MMC (58). The MMC sensitivity level we observe in Rad51C-deficient HeLa cells is thus very close to that of the *XRCC3*-deficient human cells. Although the relative hypersensitivity of Rad51C-deficient human (and chicken) cells to MMC is not as remarkable as that observed in hamster cells, the results in aggregate indicate that a role of Rad51C in HRR of interstrand crosslinks is conserved across vertebrate species.

*The cell cycle-dependence of radiosensitivity in Rad51C/XRCC3-depleted cells suggests that HRR operates mainly in the S and G<sub>2</sub>/M phases of higher eukaryotes* — Studies undertaken with various DSB repair-defective mutants have produced evidence for the contribution of HRR to IR resistance in the S and G<sub>2</sub>/M phases of the cell cycle. Disruption of the HRR-related gene *Rad54* causes a modest increase in radiosensitivity (59, 60) that is associated primarily with the late-S/G<sub>2</sub> phase (49). By contrast, the NHEJ-defective CHO mutants for *XRCC4*, *Ku86* and *DNA-PKcs* (the XR-1, xrs5/6, and V3 cell lines, respectively) are highly sensitive to IR in G<sub>1</sub> and early S phases, compared to the wild-type, but are more IR-resistant in late S/G<sub>2</sub> (61-64). A similar pattern was reported for murine pre-B cells carrying the *scid* mutation (65). These results suggest that DSBs occurring in replicated DNA are repaired efficiently by HRR. HRR is likely

avored in the S-phase cells due to the presence of sister chromatids as proximal repair templates (66). During the normal cell cycle, Rad51 transcription is induced in the S and G<sub>2</sub> phases (67), and Rad51 protein expression is found to be lowest in G<sub>1</sub>, increasing in S, and reaching a maximum in G<sub>2</sub>/M (68). Mammalian Rad51 forms discrete nuclear foci during the S phase (69). All of this evidence argues that the critical function of HRR takes place in the S/G<sub>2</sub> phase of the cell cycle.

Our results with HeLa cells co-depleted for Rad51C and XRCC3 further support this view. We examined the radiosensitivity of Rad51C siRNA-depleted HeLa cells using asynchronous cultures, and synchronized G<sub>1</sub> and S+G<sub>2</sub> populations. The asynchronous cells displayed moderately increased sensitivity to IR, which is in consistent with the phenotype shown by other HR-defective mutants, *i.e.* Rad54-deficient chicken DT40 (59) and mouse embryonic stem cells (60); Rad51C, XRCC2 or XRCC3-mutant hamster cells (13, 27, 28); and Rad51 paralog-knockout DT40 cells (25, 26). When the radiosensitivities of G<sub>1</sub>- and S+G<sub>2</sub>-phase cells were investigated separately, however, distinct IR responses were observed for these two populations. In G<sub>1</sub> phase, Rad51C/XRCC3-deficient cells are no more sensitive to IR than controls. In S+G<sub>2</sub> phase, however, the Rad51C/XRCC3-deficient cells show increased IR sensitivity relative to controls. In a related manner, it has been previously reported that hamster V79 parental cells were sensitive to IR at the G<sub>1</sub>/S border whereas they are IR-resistant in late S phase; however, the *irs-1* (XRCC2-mutant) cells lost the S-phase-dependent resistance to IR (48). Current models propose that, in mammalian cells, NHEJ dominates DSB repair in G<sub>1</sub>/early S, but that HRR and NHEJ both contribute substantially during late S/G<sub>2</sub> (50, 65). The cell cycle-dependent radiosensitivity we observe in Rad51C siRNA-treated HeLa cells strongly supports a role for human Rad51C and/or XRCC3 in S/G<sub>2</sub> phase-specific HRR.

In conclusion, our studies demonstrated that: (i.) RNA interference effectively depletes Rad51C in human cells; (ii.) Depletion of Rad51C destabilizes the XRCC3 protein; (iii.) Inhibition of Rad51C impairs HRR of chromosomal DSBs; (iv.) Rad51C-deficient HeLa cells are sensitive to MMC and IR and; (v.) Radiosensitivity of Rad51C-deficient HeLa cells is associated with the S/G<sub>2</sub> phase of the cell cycle. These findings are the first *in vivo* evidence for the functions of human Rad51C in repairing DNA DSBs through homologous recombination.

### ACKNOWLEDGEMENTS

We thank Benjamin Chen and David Collins for discussions about the siRNA experiments and Xiaoyen Lao for assistance with  $\gamma$ -ray irradiation and flow cytometry. We also thank Alice Yamada for sharing the protocol of MMC survival and Kevin Peet for his editorial contributions.

### REFERENCES

1. Khanna, K.K., and Jackson, S.P. (2001) *Nat. Genet.* **27**, 247-254
2. Pierce, A.J., Stark, J.M., Araujo, F.D., Moynahan, M.E., Berwick, M., and Jasin, M. (2001) *Trends Cell Biol.* **11**, S52-59
3. Thompson, L.H., and Schild, D. (1999) *Biochimie* **81**, 87-105
4. Thompson, L.H., and Schild, D. (2001) *Mutat. Res.* **477**, 131-153
5. Baumann, P., Benson, F.E., and West, S.C. (1996) *Cell* **87**, 757-766
6. Baumann, P., and West, S.C. (1997) *EMBO J.* **16**, 5198-5206

7. Albala, J.S., Thelen, M.P., Prange, C., Fan, W., Christensen, M., Thompson, L.H., and Lennon, G.G. (1997) *Genomics* **46**, 476-479
8. Rice, M.C., Smith, S.T., Bullrich, F., Havre, P., and Kmiec, E.B. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 7417-7422
9. Cartwright, R., Dunn, A.M., Simpson, P.J., Tambini, C.E., and Thacker, J. (1998) *Nucleic Acids Res.* **26**, 1653-1659
10. Dosanjh, M.K., Collins, D.W., Fan, W., Lennon, G.G., Albala, J.S., Shen, Z., and Schild, D. (1998) *Nucleic Acids Res.* **26**, 1179-1184
11. Pittman, D.L., Weinberg, L.R., and Schimenti, J.C. (1998) *Genomics* **49**, 103-111
12. Kawabata, M., and Saeki, K. (1999) *Biochim. Biophys. Res. Commun.* **257**, 156-162
13. Liu, N., Lamerdin, J.E., Tebbs, R.S., Schild, D., Tucker, J.D., Shen, M.R., Brookman, K.W., Siciliano, M.J., Walter, C.A., Fan, W., Narayana, L.S., Zhou, Z.Q., Adamson, A.W., Sorensen, K.J., Chen, D.J., Jones, N.J., and Thompson, L.H. (1998) *Mol. Cell* **1**, 783-793
14. Cartwright, R., Tambini, C.E., Simpson, P.J., and Thacker, J. (1998) *Nucleic Acids Res.* **26**, 3084-3089
15. Johnson, R.D., Liu, N., and Jasin, M. (1999) *Nature* **401**, 397-399
16. Tebbs, R.S., Zhao, Y., Tucker, J.D., Scheerer, J.B., Siciliano, M.J., Hwang, M., Liu, N., Legerski, R.J., and Thompson, L.H. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 6354-6358
17. Pierce, A.J., Johnson, R.D., Thompson, L.H., and Jasin, M. (1999) *Genes Dev.* **13**, 2633-2638
18. Masson, J.-Y., Tarsounas, M.C., Stasiak, A.Z., Stasiak, A., Shah, R., McIlwraith, M.J., Benson, F.E., and West, S.C. (2001) *Genes Dev.* **15**, 3296-3307

19. Sigurdsson, S., Komen, S.V., Bussen, W., Schild, D., Albala, J.S., and Sung, P. (2001) *Genes Dev.* **15**, 3308-3318
20. Wiese, C., Collins, D.W., Albala, J.S., Thompson, L.H., Kronenberg, A., and Schild, D. (2002) *Nucleic Acids Res.* **30**, 1001-1008
21. Liu, N., Schild, D., Thelen, M.P., and Thompson, L.H. (2002) *Nucleic Acids Res.* **30**, 1009-1015
22. Miller, K.A., Yoshikawa, D.M., McConnell, I.R., Clark, R., Schild, D., and Albala, J.S. (2002) *J. Biol. Chem.* **277**, 8406-8411
23. Schild, D., Lio, Y.-C., Collins, D.W., Tsomondo, T., and Chen, D.J. (2000) *J. Biol. Chem.* **275**, 16443-16449
24. Lio, Y.-C., Mazin, A.V., Kowalczykowski, S.C., and Chen, D.J. (2003) *J. Biol. Chem.* **278**, 2469-2478
25. Takata, M., Sasaki, M.S., Tachiiri, S., Fukushima, T., Sonoda, E., Schild, D., Thompson, L.H., and Takeda, S. (2001) *Mol. Cell Biol.* **21**, 2858-2866
26. Takata, M., Sasaki, M.S., Sonoda, E., Fukushima, T., Morrison, C., Albala, J.S., Swagemakers, S.M., Kanaar, R., Thompson, L.H., and Takeda, S. (2000) *Mol. Cell Biol.* **20**, 6476-6482
27. French, C.A., Masson, J.-Y., Griffin, C.S., O'Regan, P., West, S.C., and Thacker, J. (2002) *J. Biol. Chem.* **277**, 19322-19330
28. Godthelp, B.C., Wiegant, W.W., van Duijn-Goedhart, A., Scharer, O.D., van Buul, P.P., Kanaar, R., and Zdzienicka, M.Z. (2002) *Nucleic Acids Res.* **30**, 2172-2182
29. Bass, B.L. (2000) *Cell* **101**, 235-238
30. Sharp, P.A. (2001) *Genes Dev.* **15**, 485-490

31. Zamore, P.D. (2001) *Nat. Struct. Biol.* **8**, 746-750
32. Hannon, G.J. (2002) *Nature* **418**, 244-251
33. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C. (1998) *Nature* **391**, 806-811
34. Montgomery, M.K., Xu, S., and Fire, A. (1998) *Proc. Natl. Acad. Sci. USA* **95**, 15502-15507
35. Caplen, N.J., Parrish, S., Imani, F., Fire, A., and Morgan, R.A. (2001) *Proc. Natl. Acad. Sci. USA* **98**, 9742-9747
36. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001) *Nature* **411**, 494-498
37. Harborth, J., Elbashir, S.M., Bechert, K., Tuschl, T., and Weber, K. (2001) *J. Cell Sci.* **114**, 4557-4565
38. Elbashir, S.M., Harborth, J., Weber, K., and Tuschl, Y. (2002) *Methods* **26**, 199-213
39. Liu, Y., Masson, J.-Y., Shah, R., O'Regan, P., and West, S.C. (2004) *Science* **303**, 243-246
40. Lalande, M. (1990) *Exp. Cell Res.* **186**, 332-339
41. Watson, P.A., Hanauske-Abel, H.M., Flint, A., and Lalande, M. (1991) *Cytometry* **12**, 242-246
42. Talwar, N., and Redpath, J.L. (1997) *Radiat. Res.* **148**, 48-53
43. Taylor, I.W. (1980) *J. Histochem. Cytochem.* **28**, 1021-1024
44. Rouet, P., Smith, F., and Jasin, M. (1994) *Mol. Cell Biol.* **14**, 8096-8106
45. Choulika, A., Perrin, A., Dujon, B., and Nicolas, J.F. (1995) *Mol. Cell Biol.* **15**, 1968-1973
46. Brenneman, M.A., Weiss, A.E., Nickoloff, J.A., and Chen, D.J. (2000) *Mutat. Res.* **459**, 89-97



47. Brenneman, M.A., Wagener, B.M., Miller, C.A., Allen, C.P., and Nickoloff, J.A. (2002) *Mol. Cell* **10**, 387-395
48. Cheong, N., Wang, X., Wang, Y., and Iliakis, G. (1994) *Mutat. Res.* **314**, 77-85
49. Takata, M., Sasaki, M.S., Sonoda, E., Morrison, C., Hashimoto, M., Utsumi, H., Yamaguchi-Iwai, Y., Shinohara, A., and Takeda, S. (1998) *EMBO J.* **17**, 5497-5508
50. Rothkamm, K., Krüger, I., Thompson, L.H., and Löbrich, M. (2003) *Mol. Cell Biol.* **23**, 5706-5715
51. Terasima, T., and Tolmach, L.J. (1963) *Biophys. J.* **3**, 11-33
52. Terasima, T., and Tolmach, L.J. (1963) *Science* **140**, 490-492
53. Phillips, R.A., and Tolmach, L.J. (1966) *Radiat. Res.* **29**, 413-432
54. Belli, J.A., and Shelton, M. (1969) *Science* **165**, 490-492
55. Barendsen, G.W., van Bree, C., and Franken, N.A. (2001) *Int. J. Oncol.* **19**, 247-56
56. Kurumizaka, H., Ikawa, S., Nakada, M., Enomoto, R., Kagawa, W., Kinebuchi, T., Yamazoe, M., Yokoyama, S., and Shibata, T. (2002) *J. Biol. Chem.* **277**, 14315-14320
57. French, C.A., Tambini, C.E., and Thacker, J. (2003) *J. Biol. Chem.* **278**, 45445-45450
58. Yoshihara, T., Ishida, M., Kinomura, A., Katsura, M., Tsuruga, T., Tashiro, S., Asahara, T., and Miyagawa, K. (2004) *EMBO J.* **23**, 670-680
59. Bezzubova, O., Silbergleit, A., Yamaguchi-Iwai, Y., Takeda, S., and Buerstedde, J.M. (1997) *Cell* **89**, 185-193
60. Essers, J., Hendriks, R.W., Swagemakers, S.M., Troelstra, C., de Wit, J., Bootsma, D., Hoeijmakers, J.H., and Kanaar, R. (1997) *Cell* **89**, 195-204
61. Stamato, T.D., Weinstein, R., Giaccia, A., and Mackenzie, L. (1983) *Somat. Cell Genet.* **9**, 165-173

62. Giaccia, A., Weinstein, R., Hu, J., and Stamatou, T.D. (1985) *Somat. Cell Mol. Genet.* **11**, 485-491
63. Whitmore, G.F., Varghese, A.J., and Gulyas, S. (1989) *Int. J. Radiat. Biol.* **56**, 657-665
64. Jeggo, P.A. (1990) *Mutat. Res.* **239**, 1-16
65. Lee, S.E., Mitchell, R.A., Cheng, A., and Hendrickson, E.A. (1997) *Mol. Cell Biol.* **17**, 1425-1433
66. Johnson, R.D., and Jasin, M. (2000) *EMBO J.* **19**, 3398-3407
67. Flygare, J., Benson, F., and Hellgren, D. (1996) *Biochim. Biophys. Acta* **1312**, 231-236
68. Chen, F., Nastasi, A., Shen, Z., Brenneman, M., Crissman, H., and Chen, D.J. (1997) *Mutat. Res.* **384**, 205-211
69. Tashiro, S., Kotomura, N., Shinohara, A., Tanaka, K., Ueda, K., and Kamada, N. (1996) *Oncogene* **12**, 2165-2170

#### FOOTNOTES

<sup>1</sup> The abbreviations used are: DSB, double-strand break; NHEJ, non-homologous end joining; HR, homologous recombination; HRR, homologous recombinational repair; MMC, mitomycin C; RNAi, RNA interference; siRNA, small interfering RNA; IR, ionizing radiation; PLD, potentially lethal damage.

#### FIGURE LEGENDS

**Fig. 1. Inhibition of Rad51C suppresses XRCC3 expression and other Rad51 family proteins.** A, Western analysis of the endogenous levels of Rad51 and Rad51 paralogs. HeLa cells were individually transfected with Rad51C siRNA #1 and #2 duplexes or mock-transfected (control). On days 2, 3 and 4 post-transfection, cells were harvested and subjected to Western blotting analysis with  $\alpha$ -Rad51C,  $\alpha$ -XRCC3,  $\alpha$ -Rad51,  $\alpha$ -Rad51B,  $\alpha$ -Rad51D,  $\alpha$ -XRCC2, and  $\alpha$ -QM antibodies. QM is a transcription factor and was used as a loading control. B, Quantification and statistical analysis of the protein levels of Rad51 and Rad51 paralogs. The means and standard deviations for three independent experiments are shown.

**Fig. 2. Rad51C depletion results in a reduced frequency in homologous recombination in human HT1080 cells.** A, Homologous recombinational repair of a site-specific chromosomal break in the reporter locus. PGK: mouse phosphoglycerate kinase enhancer/promoter. Pac: puromycin acetyltransferase gene (confers puromycin resistance). Deletion mutation/I-SceI cleavage site: inactivates the pac gene and creates a site for chromosomal cleavage by I-SceI endonuclease. pA: SV40 polyadenylation region. Ori/Amp: bacterial origin of replication and ampicillin resistance gene (needed for propagation of the vector as a plasmid). CMV-BSD: blasticidin deaminase (blasticidin resistance) gene, with Cytomegalovirus promoter/enhancer and bovine growth hormone polyA signal. Heavy line indicates flanking chromosomal sequence. B, Transfection of siRNA duplexes inhibits the expression of Rad51C in HT1080-1885 cells. HT1080-1885 cells were transfected with Rad51C siRNA #1 or siRNA #2, or mock-transfected with Oligofectamine alone (control). On day 2 post-siRNA transfection, cells were harvested and subjected to Western blotting analysis with  $\alpha$ -Rad51C and  $\alpha$ -QM antibodies. C, siRNA depletion of Rad51C causes a reduction in HR frequency. On day 2 post-siRNA transfection,

HT1080-1885 cells were transfected for expression of I-SceI endonuclease. Each transfection was replated in duplicate for HR frequency measurements. The HR frequency was calculated as the average number of colonies per dishes divided by the plating efficiency for that transfection, divided by 120,000 (the total number of cells plated). The means and standard deviations for six experiments are shown.


**Fig. 3. Inhibition of Rad51C causes increased sensitivity to mitomycin C and  $\gamma$ -rays in asynchronous HeLa cells.** A, MMC sensitivity: HeLa cells were transfected with Rad51C siRNA #1 or siRNA #2, or mock-transfected with Oligofectamine alone (control). On day 2 post-siRNA transfection, cells were seeded and treated with various concentrations of MMC (0, 0.2, 0.4, 0.8, 1, 2  $\mu$ M) for 1 h. B,  $\gamma$ -ray sensitivity: HeLa cells were transfected with Rad51C siRNA #1 or siRNA #2, or mock-transfected with Oligofectamine alone (control). On day 2 post-siRNA transfection, cells were seeded and treated with various doses of  $\gamma$ -rays (0, 4, 6, 8, 10 Gy). The surviving fractions were calculated and normalized for plating efficiency. The data points graphed are the means of four independent experiments; the error bars represent standard deviations.

**Fig. 4. Distribution of HeLa cells in the phases of the cell cycle as a function of time after release from mimosine treatment.** On day 2 post-transfection, the mock-transfected (A) and Rad51C siRNA #1-treated (B) cells were exposed to 200  $\mu$ M mimosine for 16 h, at which time the cultures were rinsed three times with fresh media to remove mimosine. Subsequently, cells were collected and fixed at the indicated time points (0, 6.5, 10, 12, 13.7 h) and analyzed by flow

cytometry. The time points chosen for irradiation of the G<sub>1</sub>- and S+G<sub>2</sub>-enriched populations are indicated by arrows.


**Fig. 5. Rad51C-deficient HeLa cells show increased sensitivity to  $\gamma$ -rays in S+G<sub>2</sub>/M phase, but not in G<sub>1</sub> phase.** After irradiation with various doses (0, 4, 6, 8, 10 Gy) of  $\gamma$ -rays, mock- (control) and Rad51C siRNA-transfected cells were either (A) immediately replated in triplicate for colony formation assay, or (B) returned to incubation at 37°C for 18 h, and then replated in triplicate for colony formation assay. The surviving fractions were calculated and normalized for plating efficiency. The means and standard deviations for two independent experiments are shown.

**A**



**Fig. 1**

**B**



**Fig. 1**






Fig. 2



**B**



**C**



**Fig. 2**





Fig. 3





Fig. 4





Fig. 5